Welcome and good morning on our behalf as well. As usual, let's start with some overall highlights from the quarter. We can begin with the demand situation. Order intake continued to improve versus last year. Organically, the order intake increased by 1%, with slightly more than half of the companies showing a positive order intake.
The stronger segments were medical technology and pharmaceuticals, energy, and parts of the process industry.
Net sales were unchanged from last year, both in total and organically. Contributions from acquisitions improved compared to the last quarters and were at a good level. EBITA margin came in at 13.3%, in line with underlying margin last year, and we will comment more on this further on in the presentation.
Operating cash flow was also in line with last year. Our companies continue to improve management of working capital. Inventories are lower than last year, and the inventory in relation to sales is on a historically low level.
In Q1, we managed to acquire two larger companies, and we also made one more acquisition in April, adding 625 million in revenue on a yearly basis. And the pipeline continues strong.
We are obviously not satisfied with the overall performance in the quarter.
However, there is good progress in several areas which I will comment more upon throughout the presentation.
Looking more specifically at the order intake and sales trends, demand was stronger than last year, but still varied across companies, geographies and segments. Book to bill is seasonally strong in Q1 for us, but improved from 105% last year to 107% now.
As mentioned, companies with customers within Medtech/Pharma, the energy sector, and parts of the Process Industry experienced strong demand, while order intake for companies with customers in infrastructure, construction, and engineering was aggregated slightly down compared to last year. In terms of sales, acquisitions contributed positively, with 5%, a sequential improvement from the 4% we had in Q4 2025.
However, currency movements had a negative impact of 5%, and organic sales were flat, leading to an unchanged top line development in total. We had a stronger order book coming into the quarter, but the sales development was impacted by a weak start of the year, mainly due to the challenging weather and also by the composition of the order book, with a higher share of orders connected to the energy sector and the process industry with longer lead times in general, the sales development gradually improved during the quarter, starting with a weak January and ending with a strong March.
Moving into sales per market in the Nordics, sales were up in Norway, flat in Sweden and Finland, and down in Denmark. Flow technology for marine applications, water treatment, and the energy sector were drivers for the positive development in Norway. While the lower sales to Novo Nordisk were the main reason for the decline in Denmark. Starting with the Benelux, sales were lower within engineering and in some of the life science companies.
UK/Ireland experienced good development within, for instance, railway rolling stock, and Germany was flat overall but showed a slightly improved situation in the engineering sector. Switzerland and Austria were weaker, mainly due to lower sales within valves for power generation and within the construction segment in North America.
Sales improved compared to last year due to good development within medical technology. In Asia, sales declined due to challenging comparables from last year in the marine segment.
In terms of profitability. Total EBIT decreased 2%, corresponding to an EBIT margin of 13.3% compared to 13.6% last year. However, in Q1 last year, we had some positive one-offs, so the underlying EBITDA margin was 13.3% in line with this year's Ebit margin. The main reason for the EBITDA margin not being on a higher level is the organic sales development. In combination with slightly higher expenses, underlying expenses grew around 1%. But on top of this, we also had some non-recurring costs for downsizing.
Patrik Johnson will explain more details in his presentation. But perhaps good to elaborate on the type of companies we have and why some of them haven't reduced more. If we go back to the situation late 2025, then I would say that the expectation was that in 2026, we would see better and better order and sales situations, and this could be based on that. We had an organic order intake improvement of plus 3% both in Q3 and Q4 last year. So most companies had a somewhat positive outlook, I would say, for 2026.
And we have, as you know, quite a lot of trading companies, and they are in general lean. It's difficult to find qualified replacements. Hence, downsizing was not a top priority. And there is a hesitation to downsize if they don't really need to, linked to the situation that it is difficult to find really good replacement employees. In addition to this, we obviously also have a lot of growing companies, and they need to add people in order to manage their businesses in a professional way.
So that's a bit of an explanation. I would say, as to why we had a 1% expense increase year over year. Positive, though, that the gross margin remained strong, amounting to 36%. Very well managed. There will be some more challenges going forward.
Now, in Quarter 2, raw material price increases are occurring. But I am optimistic that our companies will handle this in a good way. We have done that for very many years, historically. Looking at the sales development per business area. Two of them grew organically. Industrial and Engineering and Life Science mainly as a broad result of the strengthened order book coming into the quarter in Industrial and Engineering. For instance, railway rolling stock experienced a positive situation.
They have had large orders from. From companies like Alstom Porterbrook in the UK. They also had a good situation in terms of specialty chemicals, and I think it's worth noting that they had an all-time high order intake in March during the quarter. Life science is next. Certain companies within medical technology experienced good development. We usually comment on the single use business. I think that's still good. And we made a Spanish acquisition, our first company in Spain last year, and they are into single use. And the first quarter was an all-time high for them. So good start this year for them in Indutrade just to give some other flavors.
We have a broad portfolio of medtech companies. It's everything from selling communication equipment to Swedish hospitals.
And that business has grown really well. We have a growing business in Poland.
We sell medical equipment and consumables to hospitals.
And that's also a growing business. We have companies in Ireland which sell medical technology to large international customers and in the quarter now sold successfully. To the US.
So it's not a single company. It's a broad base of companies doing well in medical technology.
Infrastructure and construction and technology and systems solutions continue to be weaker due to demand being subdued on the back of the general market uncertainty and lower investment levels in some customer segments. Process, Energy & Water had a good order book coming into the quarter, but there are generally longer lead times within the energy sector and the process industry. So the -3% is more of a timing effect. They now have a record high order book and good conditions for stronger development going forward. And March was actually the second best month ever in terms of order intake for Process, Energy & Water.
In general, I would say that the challenging weather in the beginning of the year also impacted the sales development negatively, mainly in Infrastructure & Construction and Process, Energy & Water.
If we then turn to profitability for the business areas, it was three business areas improving the EBITA margin in the quarter. Industrial and Engineering had the strongest margin development, supported by the gross margin improvements, leverage on the organic sales and margin accretive acquisitions. Infrastructure and Construction has for a longer time worked with restructuring measures and kept costs in a really good way, and some divestments also improved its margin. The gross margin further strengthened due to good sales development within the medtech cluster, as I mentioned, as well as margin accretive acquisitions contributing positively.
Process, Energy & Water was impacted by the lower sales, as I talked about earlier, and the EBITA margin development in Technology & Systems Solutions was mainly driven by lower organic sales, together with slightly higher expense levels.
Acquisitions. Positive situation. So far this year, we have acquired three companies, of which two were slightly larger, with a total annual turnover of 625 million SEK. We are very glad to have welcomed Belman A/S, CAT Ricambi S.r.l. We also welcome Axotan AB to the group. They all have a good track record of sustainable, profitable growth and are also margin accretive to the group.
The average company size was slightly lower than a normal acquisition year for Indutrade, and this year so far it's slightly higher. This shouldn't be seen as a strategic shift. We are opportunity oriented, as you know, and we act on opportunities we believe to be accretive and successful.
Consequently, there will be times when we have periods of larger acquisitions and periods with smaller acquisitions being made. The acquired EBITDA was at a high level in quarter one, as can be seen on the graph to the right, just over 70 million SEK. Also, looking at the EBITDA margin of the acquired companies, it was on a strong level of 19.5% for the quarter and above 17% for rolling 12 months. Good to note that this includes transaction costs too.
The underlying margin is even higher. Our business areas are successful in the acquisition work. Being proactive and building pipeline. Our business segment leaders are spending more time on acquisitions now compared to a year ago. And the current acquisition pipeline is on a high level.
By that, I leave the word over to Patrik to comment more on the financials.